Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

A More Radical Solution

Author(s): Peter J. Lachmann

Volume 10, Issue 1, 2015

Page: [25 - 27] Pages: 3

DOI: 10.2174/1574887110666150430151051

Price: $65

Abstract

The current modifications to licensing procedures still leave a basically flawed system in place. A more radical solution is proposed that involves dispensing with Phase 3 trials and making medicines available at the end of Phase 2 to those who are fully informed of the potential risks and benefits and wish to take part in this novel procedure. The advantages include a shorter development time, lower development costs and allowing smaller companies to take medicines to the clinic. The principal obstacle is that medicines are subject to strict liability rather than the tort of negligence – and this will have to be amended in due course.

Keywords: Phase 3, strict liability.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy